Scientific advisory committee 4th meeting marks another milestone in the fight against AMR
- europevaccine
- Jul 9
- 2 min read
Updated: Oct 13
July 2025
On 4 July 2025, the PrIMAVeRa consortium successfully held its annual Scientific Advisory Committee (SAC) meeting, bringing together 19 participants, including leading scientists, industry experts, and public health stakeholders, to discuss progress and strategic directions for the final phase of the project.
PrIMAVeRa, short for Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance, is an ambitious EU-funded initiative aimed at quantifying how vaccines and monoclonal antibodies can help reduce antimicrobial resistance (AMR) in Europe.
Highlights from this year’s meeting included:
A detailed review of progress and key achievements across Work Packages 2 to 5.
In-depth discussions on developing a more general and flexible modelling approach, moving beyond pathogen-specific case studies to provide broader policy-relevant insights.
Exchange of views on how to refine cost-effectiveness analyses and visualisations to better address the needs of policymakers, funding bodies, healthcare providers and other relevant stakeholders.
Dialogue on long-term sustainability, including strategies for data sharing, tool maintenance, and continuous user engagement beyond the project’s lifetime.
Participants also discussed practical steps to ensure that the project’s tools and outputs remain accessible and impactful after the end of the grant period.
Irina Meln, Project Lead at the European Vaccine Initiative, who moderated the meeting, noted: “Working closely with our SAC is invaluable. Their diverse expertise helps us ensure that PrIMAVeRa’s tools and evidence respond to the real-world needs of those tackling AMR.”
With AMR continuing to pose a major global health threat, the PrIMAVeRa project is committed to delivering evidence and tools that help policymakers design more effective vaccination strategies to tackle antibiotic resistance and protect public health.
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
